Scalper1 News
Big-cap biotech United Therapeutics (UTHR) disappointed investors for the second quarter in a row Tuesday, as it missed Q2 estimates and its new drug launch continued to underwhelm. The stock hit a five-month low in early trading on the stock market today . Revenue in the quarter grew 7.6% over the year-earlier quarter to $347.2 million, about $13 million below analysts’ consensus, according to Thomson Reuters. Earnings rose 14% to $2.55 a share, Scalper1 News
Scalper1 News